SKPin C1 is a potent and selective inhibitor of Skp2-mediated p27 degradation. It selectively inhibited Skp2-mediated p27 degradation by reducing p27 binding through key compound-receptor contacts. In cancer cells, the compounds induced p27 accumulation in a Skp2-dependent manner and promoted cell-type-specific blocks in the G1 or G2/M phases. SKPin C1 is a useful chemical probe selectively targeting SCF-Skp2 protein-protein interface, may provide a new avenue of cancer treatment with enhanced specificity over Bortezomib.

How to Use:

• In vitro: SKPin C1 was used at 10 µM final concentration in various in vitro assays.
• In vivo: n/a

Reference:

1. 1. Wu L, et al. Specific small molecule inhibitors of Skp2-mediated p27 degradation. (2012) Chem Biol. 19(12):1515-24.

Products are for research use only. Not for human use.